Clustering data with hclust algorithm for Metabolomics of intensive weight management clinic (IWMC) weight loss (Study ST000744)
Reversed phase POSITIVE ION MODE (Analysis AN001163)Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 |
---|---|---|---|---|---|---|---|---|---|---|---|
3-(4-HYDROXYPHENYL)LACTIC ACID (M+H)+ | ME206328 | 0.88 | NA | 0.59 | 0.25 | NA | 1.42 | 1.59 | NA | 1.18 | 0.98 |
1-METHYLXANTHINE (M+H)+ | ME206319 | 0.87 | 0.95 | 1.01 | 1.00 | 1.01 | 1.08 | 0.93 | 1.04 | 1.00 | 1.07 |
5^-METHYLTHIOADENOSINE (M+H)+ | ME206335 | 0.96 | 1.01 | 1.10 | 1.16 | 0.87 | 0.94 | 0.86 | 0.73 | 1.12 | 1.10 |
4-PYRIDOXIC ACID (M+NA)+ | ME206333 | 0.52 | 1.53 | 0.81 | 0.50 | 0.46 | 0.35 | 0.73 | 1.23 | 0.62 | 3.87 |
ADENOSINE 5^-MONOPHOSPHATE (M+H)+ | ME206338 | 0.92 | 0.91 | 0.94 | 0.69 | 0.70 | 1.71 | 0.46 | 1.48 | 1.11 | 2.00 |
2-HYDROXY-3-METHYLBUTYRIC ACID (M+NA)+ | ME206325 | 1.02 | 0.93 | 1.05 | 0.79 | 1.24 | 0.92 | 0.64 | 1.02 | 1.25 | 1.21 |
1-METHYLXANTHINE (M+NA)+ | ME206320 | 0.93 | 1.07 | 0.90 | 0.65 | 1.09 | 1.27 | 1.02 | 1.15 | 1.09 | 1.18 |
25-HYDROXYCHOLESTEROL (M+H)+[-H2O] | ME206327 | 1.30 | 1.77 | 0.86 | 0.99 | 1.40 | 0.94 | 1.06 | 0.41 | 0.84 | 0.58 |
3-METHYLXANTHINE (M+H)+ | ME206332 | 0.87 | 0.96 | 1.01 | 1.00 | 1.02 | 1.06 | 0.94 | 1.03 | 1.00 | 1.07 |
1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | ME206317 | 0.95 | 0.90 | 1.07 | 1.06 | 1.06 | 1.31 | 0.51 | 1.31 | 0.62 | 0.89 |
3-DEHYDROSHIKIMIC ACID (M+H)+[-H2O] | ME206329 | 1.45 | 0.90 | 1.00 | 0.91 | 0.95 | 0.73 | 1.18 | 0.83 | 1.32 | 0.98 |
18:0 LYSO-PE (M+H)+ | ME206324 | 1.26 | 1.19 | 1.23 | 0.89 | 0.84 | 0.85 | 0.77 | 0.91 | 0.80 | 1.32 |
ACETYLCARNITINE (M+H)+ | ME206336 | 0.81 | 0.52 | 0.87 | 0.76 | 0.83 | 0.80 | 0.49 | 0.83 | 1.72 | 2.85 |
3-METHOXYTYROSINE (M+H)+ | ME206331 | 1.19 | 0.89 | 1.32 | 1.07 | 0.66 | 1.05 | 0.94 | 0.49 | 1.27 | 0.83 |
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ | ME206334 | 0.65 | 1.23 | 0.91 | 0.89 | 0.78 | 1.25 | 0.63 | 1.02 | 1.73 | 1.16 |
16:0 LYSO PC (M+NA)+ | ME206322 | 1.03 | 0.94 | 1.03 | 0.86 | 1.01 | 0.96 | 0.76 | 1.38 | 1.15 | 1.03 |
16:0-18:0 PC (M+H)+ | ME206323 | 0.92 | 0.87 | 0.87 | 1.04 | 1.16 | 0.93 | 1.17 | 1.19 | 0.91 | 0.99 |
16:0 LYSO PC (M+H)+ | ME206321 | 0.88 | 0.96 | 0.99 | 1.06 | 1.05 | 1.00 | 0.98 | 0.89 | 1.00 | 1.10 |
1-METHYLADENOSINE (M+H)+ | ME206318 | 0.92 | 0.97 | 1.05 | 0.98 | 0.84 | 1.08 | 0.96 | 0.94 | 1.16 | 1.10 |
3-HYDROXYBENZALDEHYDE (M+H)+[-H2O] | ME206330 | 1.05 | 0.64 | 1.68 | 1.77 | 0.45 | 0.41 | 0.51 | 0.90 | 0.72 | 0.99 |
Factors:
F1 | Gender:female | Glycemic status:Diabetic | Neuropathy:Neuropathy |
F2 | Gender:female | Glycemic status:Diabetic | Neuropathy:no neuropathy |
F3 | Gender:female | Glycemic status:Pre-diabetic | Neuropathy:Neuropathy |
F4 | Gender:female | Glycemic status:Pre-diabetic | Neuropathy:no neuropathy |
F5 | Gender:male | Glycemic status:Diabetic | Neuropathy:Neuropathy |
F6 | Gender:male | Glycemic status:Diabetic | Neuropathy:no neuropathy |
F7 | Gender:male | Glycemic status:Normoglycemic | Neuropathy:Neuropathy |
F8 | Gender:male | Glycemic status:Normoglycemic | Neuropathy:no neuropathy |
F9 | Gender:male | Glycemic status:Pre-diabetic | Neuropathy:Neuropathy |
F10 | Gender:male | Glycemic status:Pre-diabetic | Neuropathy:no neuropathy |